<SEC-DOCUMENT>0001193125-14-373164.txt : 20141016
<SEC-HEADER>0001193125-14-373164.hdr.sgml : 20141016
<ACCEPTANCE-DATETIME>20141016061000
ACCESSION NUMBER:		0001193125-14-373164
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20141016
FILED AS OF DATE:		20141016
DATE AS OF CHANGE:		20141016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		141158750

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d806126d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 16 October 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LIMITED</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(ASX: NRT)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center">


<IMG SRC="g806126tx_pg003.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16&nbsp;October 2014 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN ANNOUNCES CAPITAL-RAISING VIA
ASX BOOKBUILD FACILITY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16&nbsp;October 2014:</B> Novogen (ASX: NRT; NASDAQ: NVGN) today announced that it is raising capital in Australia and the
USA through the issue of ordinary shares and options via a panel of stockbrokers assembled by the Company, and via the ASX Bookbuild facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer
Terms Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the offer (the <B>Offer</B>) are in accordance with the shareholder approval received at the Company&#146;s General Meeting
held on August&nbsp;13. Therefore no further security holder approval will be necessary for this issue. Those terms are the issuance of up to 80&nbsp;million ordinary shares and up to 80&nbsp;million options to raise up to a maximum of A$10,000.000.
The shares can be issued up to a 20% discount to market, the market price determined by a five-day VWAP immediately prior to the offer being opened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors also will be issued one option per share acquired. Each option will be issued on the following terms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It may be exercised by its holder at any time up to the first anniversary of its issue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On exercise it will entitle the option holder to one share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The exercise price will be 90% of the five-day VWAP immediately preceding the issue of the shares pursuant to the exercise of the option; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The options may not be traded except in accordance with section 708 of the Corporations Act (for example to other sophisticated or institutional investors). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in the Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offer generally is
being made available via the ASX Bookbuild facility that opens the offer to a broad number of Australian stockbrokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares and options will be
issued in compliance with section 708 of the Corporations Act. Therefore it is intended that the issue be available to sophisticated or institutional investors only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the Technical Lead Manager for the Bookbuild facility will be announced early next week. In the meantime, any persons interested in applying for
shares pursuant to this offer should contact their broker or the Advisor to the Offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applications for shares and options under the Offer must be made by brokers on behalf of their clients by
submitting an application on behalf of an eligible applicant via the ASX Bookbuild facility using the ASX code NRTXBB prior to the close of the Bookbuild. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any allocation of shares and options resulting from the application made through the ASX Bookbuild facility will be binding on the applicant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Dates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Price determination:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">5-day VWAP (27/10/2014 to 31/10/2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Price announcement:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">3 November 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offer Open:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Monday 3 November 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offer Close:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">3 pm, 7 November 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Settlement for successful allocations will occur (T+4) after the Offer Close via the Chess Primary Market Facility on a DVP basis.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note that the application for shares and options will be based on a fixed price to be announced at 10 am 3&nbsp;November 2014.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds will be used for
general working capital and to fund the Company&#146;s R&amp;D programs. However, the primary use of funds is to underwrite the transition of the Company&#146;s lead product, Cantrixil, into the clinic. Cantrixil has been developed by the
Novogen-Yale University joint venture company, CanTx Inc., as a novel therapeutic drug for the treatment of cancers within the abdominal and pleural cavities. Cantrixil is the first experimental drug to be purpose-built to be injected into cavities
such as the peritoneal cavity and pleural cavity in order to act directly on cancer stem cells, the cells primarily responsible for tumor growth and spread, and for tumor recurrence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eventual primary clinical indication of Cantrixil is first-line therapy in combination with carboplatin for ovarian cancer following primary diagnosis and
surgical debulking. The rationale is to use the active component of Cantrixil, TRX-E-002-1, to kill ovarian cancer stem cells and their daughter cells before the cancer becomes widely disseminated. Eradicating the cancer stem cells is considered by
many to be fundamental to eradicating the cancer and preventing tumor recurrence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While first-line therapy is the ultimate objective, the required
starting point for clinical studies has to be salvage therapy in patients with late-stage cancer. Two clinical strategies are being pursued to this end, and it is this dual strategy of two Phase 1 studies that is to be the main focus of the current
fund-raising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil currently is undergoing an Investigational New Drug (IND) program ahead of plans to have it in the
clinic in mid-2015 in both indications. The funds will be applied to that IND process, as well as to initiating two Phase 1 studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first Phase 1
study will be in women with late-stage ovarian cancer. In order to expedite patient enrolment, this study will involve a number of clinics in the US, with the Yale Cancer Center in New Haven, CT, the primary site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second Phase 1 study will be in patients with malignant ascites. Malignant ascites is the accumulation of fluid in the peritoneal cavity due to the spread
of cancer cells. It occurs as a late-stage condition in patients with ovarian, gastric, breast, colorectal and pancreatic cancers and is claimed to occur in up to 50% of patients with cancer. There is no standard of care for these patients and they
typically have survival prospects of less than 6 months. This phase 1 study is to take place in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly, Novogen CEO, said today,
&#147;The focus of this capital-raising is Cantrixil. This is an exciting product that in animal models has achieved effects on ovarian cancer not previously achieved. The idea that we might be able to offer significant clinical benefit to patients
with end-stage cancer is a thought that is pushing us to get this drug into the clinic as soon as possible.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;But as prominent as Cantrixil is
in our program, I want to emphasise that Novogen is far from being a single product or single technology company. The funds we are raising will also help to bring our pipeline drugs, Trilexium and Trx-7, closer to the clinic for neural cancers and
prostate cancer respectively, and the ATM drug technology closer to the clinic for prostate cancer and melanoma. Cantrixil will remain our primary focus, but the extended clinical program will continue and I expect to provide a strong news flow over
the next 12 months.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information about ASX Bookbuild </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information on the ASX Bookbuild Facility can be found on the ASX website on the links below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For brokers: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>http://www.asx.com.au/documents/professionals/bookbuild-trading-participant-information-sheet.pdf </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For investors: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>http://www.asx.com.au/documents/professionals/bookbuild-investor-information-sheet.pdf </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ
(&#145;NVGN&#146;). The Novogen Group includes a New Haven, Connecticut-based joint venture company, CanTx Inc., with Yale University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two
main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament
component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell&#146;s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate
cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CanTx Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CanTx Inc. is a private biotechnology
company based in New Haven, Connecticut, and established as a joint venture between Novogen and Yale University. CanTx is dedicated to the development of Cantrixil as a potential treatment for cancers in the peritoneal and pleural cavities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on our websites <U>www.novogen.com</U> and <U>www.can-tx.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advisor to the Offer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt Christensen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hill Capital </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>matthewc@hillcapital.com.au </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+(61 2) 9416 5399 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Enquiries </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CEO Novogen Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+(61 2) 9472 4100 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ian Westbrook </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westbrook Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ian@westbrookfin.com.au </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+(61 2) 9231 0922 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9472 4100 - F: +61 (0)&nbsp;2 9476 0388 | www.novogen.com
</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g806126tx_pg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g806126tx_pg003.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4P#F`P$1``(1`0,1`?_$`,4``0`!!`,!`0``````
M```````)!@<("@,$!0L"`0$``00#`0$``````````````04&!P@"`P0)"A``
M``8!`P,"`@4$"14``````0(#!`4&!P`1""$2"3$3%!5!42(6%R,E&!EQD3(D
MU98W9PKP88&QX4)BTJ34E5:&UE=WATA862H1``$#`@4"`P4""@<)``````$`
M`@,1!"$Q$@4&05%A$P=QD2(R%($(H=%"4F*2TC/3%8(CDU15%A?PP7*#-)1E
M5AC_V@`,`P$``A$#$0`_`-_C1%%_Y"O*YQ_\=$QC.KY.KM^O]RR:QG)QA4\:
ML8F2EX*KP:K=D:S6$LK*1:+&+E)9<6C,0,8[A9!?M#9$XA:'*N;;+Q!D9W-Q
M,LM=+&TU4&9H2,*Y=Z'L5F7TJ]#>8^KD-W<\<\B.TM'L8Y\Q+6N>X%Q:T@&I
M:VA=E0/;W4=`_P!)XXD`&X<?>3AO3<`K]-W#?_:W5E#UNXF331/[F_M++Q^Y
M3ZI`5%SMA_YC_P"&I!?']Y<..WD-N>0L=8WKF0<?7B@0$3:QKN2F$3'/+/6I
M%VM'/9>MFBI632>(P$C["+TAA(HD+M$P`)3"(7CQ/G6R\P\QNV%XEB`):Z@-
M*TK@3A6GO6*/57T%YKZ1VMO?<A^GEL;A^@/A<YS6OIJ#75:VFH!U#E5I&=*R
MI:O-8331$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$5)7V\U;&-)MF1;Q,-8"GT>O2]ILTT]4!-K&0D&Q6D)%VJ8PAN"39`P@4/M
M&-L4-Q$`UU3SPVT+[FX<&01M+G$Y``5)/L"J&U;7?;WN<&T;;&Z6_N96QQL`
MJ7.>0`,/$X]ABOF><R.4]IYJ<G,H\C[(5PUCKC+_`"^AP+DYC_=3%\![C"C0
M!2B4A$UPC=WCP2E*"K]VNH(`)]:*<ZY+)RKD<^XDD6X.B,=F-R]^9.%2:]U]
MQ?1[T]M?33@UEQFW#3+''JG>!0R3/^*1Q]KB0`<FAK<@L8PZ[]>HCU'Z]6>S
M$$#-9/%5??B]R/N/$#D3BGDG1_>7D,:6`CFQ0J)S%"UT"3+\OO-57*0Q!5+*
MP"JOM!O]ERFF8-C%`0NWAG(YN+\@AW*,GRJAL@K34PG$'PZ_8L<^JG`+#U)X
M9><8O@`9HR8WG..1N,;Q@<6N`/LJOIK8JR;3<T8VHV6<>RR,[2<B5B'MU8E4
M#%,1W$3;))\T,<"&.";A,BO8J3?=-0IBCU`=;V6MS!>6[+NV<'6\C0YI[@BH
M7PWWW9-QXYO-SL.[,,>XVDSHI&GHYIH:=P<P>H(*K_7>J2FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBBP\SV#LN\@/'GG*DX8G9
M"/LT8QC+Q+5J-3**V2*A27R=@L^/3*]%T0G8UF8Q`2'N650(D("500&T>=;?
M>[IQ6\L[`D7+HB0!FX#$M^T9#J13JLV_=XY%L?&/5C:]QY`QILW2&)KW9122
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M[VWJ3P:/U/O]Z?-':[:R1EJZ4@D33QM(>0&-<3ITEFJA!#*DXA9O?K4N`W_D
M%'?Q"RK_`+BZR7_E'D?]U?\`K,_:6I_^M/I?_B\'ZDW\-78PSSBXK<@[FKCS
M$.7HJW7-.$=V((`8&X0#MQ#L%VK=ZZ9*6BNPK60,T4>)BHD@HHL1,PG$G84Q
M@\%WLFZV$1GNX'LA!`)P(!.61*K>P^HW">3WPVW8MPAN+\M<X,`>TD-Q<1K8
MT&@QH,:5-*`K*_5*5[)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB((`("`AN`]!`?00^H=$RQ&:^=_P":'ALQX.<P9]:$;M83!?(I28RE
MBHRAB-(R)FCODSY(QVV65%-$BE9FY%-XU1`PF"+D4`ZBF<0T_P#5OATFS;__
M`##;XW&PN@7C2"0QU?C&&0J00?T@*U7V"^ZYZKLY_P``9MVYR@[_`+9IAG#B
M-4C0/ZJ7^FT8_IM?3`!1,C9ZZ8Y_S]"E%,NXE^9LNA0#Z/RVL2"VNA\7ER4Z
M?"?Q+9_SHG/(U-#ATJ,E)QXB>'[+GAS&J-8?%0F<-8</&98S4NV.D[CW4=$R
M)#U"C/%4SF2!:[6)L4AT1'O-'M71P`0(.LH^EG#Y]]Y&RYO8G-VZV'F.U`@.
M<#\+16E:G/P!6NGWE/56'T\]/;@;?*!O]^#!``:EKG@ZI/#RV5<#^=I'53*^
M4#DHAGOD0K0*L\24Q1Q[,]IT"@R$A8J6OJA$4+E.MTT?WNHE$E03B6AB[E33
M06%/8%C`/TYX7LG\NV]MP\#ZF<:CW:W\EONQ]I7Y7O7[GLG+.7R6%M*Y^U6!
M,;<20^2M9I#W)=\`=U:P'J5'9V#MZ%_:#_%U>%&]RL"U<JHH&0K3AC(-(S%1
ME3$N&-[$TL<6B4YB)R3-/O;S<`[$@@8[*P0JR[-8OH8BPZ\E]9LW*W?:3$?1
M%A#L,:^'B,"/%5OCF_7O&]YM]XV]Q;=P2M>W&@.DUH>X<*AP-002"*+=[P]E
M.JYMQA2,KTIV5Y6KU7F$]''`Y3JMOBT@%U'.NWH1]&/"J-UR_P!ZJD8-:ZWM
MI)8W<EI+\['$>T=#]HQ7U/XYOMER;8[;?=O-;:YB#QC723\S3XM=5I\0KDZ\
MJK::(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBCY\A7)#`
MW'.AT25S'B&*SK,V6W'BZ+CQU&5>0D>Y!B=>S6ALM:FSEC&1\''&3(X5``.J
MJY01#JIN%8V7C9Y+=?2D-T-_*<P/`)R%#3.E<\AWH%8G._66;T<L8]RL'W'\
MRNW%@CAG-NYT;!J>]SP'?"TE@`TDESVT``<YL5P>37B!N43>.2'+OOU^6X:$
M0V#Z?S0&VKH=Z4P-):Y\-6FG[@?@^)8J_P#N;E-*B+=,?_*2?PE=_%GD&H^6
MXK*^#N+O'>+XUYOR#C"VOL633I"E(5^XWBOQ+A=I77`4]NR<DLP0ZKI:*,X*
MHB*Y.S<!-L:'<*M./R17L[VR63)F^8QL>@AM?F^8U`--0[$E=;OO*<@]58+K
MC\+)H>1/LYA:/N+IUR'2!M3&VK&%CWL#O+-360-;3&HU^X@H%8((J%=?$HG7
M+(_']X2)9@BZA98LD!]CC(!(`K[_`'=?<WWUEJ/3Y6N+X=?3P_VR6BEQYOGN
M$U?,!-:YUKU\>_BO5UVKI7&H`=IM@W$``W;Z=W7K_7Z:,PIJ_=ZL5'7Q4P'`
M/F,?A?Q:G+?EJ+M%KQ9D/-$C"<?J346\<[NKUPPC/B<J6!@G/S4%#M\>1DX5
M,@*^^!Q?K'*0I@/TQOR?9!O>]_3[=Y;961C43V)^`&E<3\1'9HQS;7:WTA]0
MW>G7"9;_`),)G[-<WA;:QL`+R]C*W#V:BT>4T^6UV.,CCI&#R,L@\YV!AV#\
M`^1NXCVA^;,8?L;_`,I8!MJBN]/MX;KH^(EG;5C[,%D7_P"G^$5_Z6_I_P`,
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MK'595>-7<)L9Z#=C[3IJH)5D%/LG*`Z(J;S%R%P3Q[AD+%G3,.-\10CDX)M9
M+(=Q@JFV='$Y4^UJ>9>M!<C[A@`>P#;".B*A,.\U.(O(.:<UO!_)7">5K"S3
M(LX@J-D>KV&8324$P$4^6Q\DL\,4PD']R0?32H2JNP]R]BV-R;"87D,A4]CE
MNR5R1M]>QL[GXU"ZS=6B%RMI6P15=5<%DW\3'+F`BZZ29DTC"'<(:(KBZ(K?
MR&5\91.1Z_A^3OU2895M=?E;96L=.IZ.1N<[6()PBUF;#%UT[@)1Y#1CERFF
MNY(F*29S@43`([:(J(S1RAXX\<VS%YGK.>*L0(2:GM1PY#O%>JJCX^V_:T0E
MG[9=QT^DA1#1%YN%N7/%SD<Y?LL"\@L09??11>Z288^OU<L[]D3L*H)W+&+?
MN':1"D.`B(DV`!ZZBH19$ZE%BME/G+PUPA8!J>7^4>!\;6<I#'/7[CD^HP<P
MD4H]IO>CWLJDZ1$IAV$#E`0U%0E5<K$'(+!?(")=3V#LOXWRW#L12*^D,>7&
M!MC=B+@52H`]-"OG8M!7,@<">X!>_L-MOL.I16=F_(-P7K4O+0%AY><=(2<@
MI21@YJ)E<NTAA(1<Q$.UH^4C'[1S,IK-GT>^;G163.`&34()1`!`0U%0BN7B
M#E!QRY`K69O@W.>*<NN*6A%NK<CCJ]5VWJUIM-_,?DZ\V2#?O31J4G\I=>P9
M7M!7X=3MW[#;34(O3Q5R'P1G1Q9&F&<PXXRDZISI-C:VU#N$':%ZX[64<HI-
MYE*(>NE(]519FJ4H*@7<R9@]0'1%561\FX[P]3I?(>5;M5\=42OD;J3EPN4T
MPKU<B".W2+%J:0EY-=LR:%</'":1!.<.Y0X%#J(:(JH^;Q?RGY[\P9_)?EWS
M?YK\0E\O^5_#?&?,/B^[V?@_A/RGN;]O9UWVT1=ITZ;,FSAX\71:M&B"KITZ
M<*$1;MFR"9E5UUUE!*FDBBD03&,80`I0$1Z:EK7/<&M%7$T`\5URRQP1.FF<
M&Q,:7.)P``%23X`8E:8G-KDBYY6<CK7D5B[45Q[6`7Q_BAH;<$B5*(?*F>V$
MA-P`KNY2Y3O3FZF^'!NF(B"0:SYQ;91M-CY<M/J#\1(ZN(%?=\H\!W)7S.]7
M.=/YSRR:_C)_EL1\J!IZ1-)H3B<7DF1V)Q=2M&A8L!V[F`/4!V'^H=7&YSB`
M2L7``9+MQLU/U6;KUQJ+\\3;J9.QEJJLHD8Q3L)Z$=)OH]7<O44%%DO;5+Z'
M2.8!Z#KSW,4=S;R6\@U&1I:`>M10CW+W[9N-UM.X0[E8O,=S!(U[7#"CFD$'
M#Q'N637*F$@;*_I'*_'S)M&XVY/LW<O.Q#42E;X_Y`U\I&F6:(Z3*80:"^D"
M#*,RF`GO)JK>V`E3WU0MBG^FU;)>:OKX'::G\J+.-P/L^$^+?%9#]1-O@W'Z
M?GFT,:W:=V:7/8W*&\9074)'Y(U_UL?>.04J&DK%CW"]/MH]0Z;G#KO_`&=7
M%Y?@]8M]ZK+&V-K'FK(])Q'4@(E.WR9)%!(F,(-(&"024?6>TR*A>[X:,K=?
M;.'BR@]"E2^L0#7DO[L[;9RW4CVF%K*Z3F>FD?I$D`=R57^,[!><FWNWV:P!
M^HFD`U'Y6-S=(X]&L8'.<>@:2KA<C,EUK)62$(O&Q/A,&X5@&^&L'1Y>TJ:]
M2JZRB,O<5BD*4BLE?+$"\@LMMW*D,F(B/37@V6Q?90GZD5OY#YDAS^)V30>S
M&T:/8J_Z@<@M=XW=MEM)/^7;"(6UJ,JQ1X&0C\Z=^J9W6KP.E!8T0';[/J`#
MMTWVZ:KS"":..!5@'"E%Z-=M5DH5IJN0:2]&.NM$GXNVU=^&_:C,0K@CA)%8
MOHJS?I`=NX3'[*J"QR#N`CKS7=F-PLGVD^+,<.X/1539MUNMDW6#=;%Q9<P2
MM>TCHYK@0?>!7N,,ENU<<LY5CD?ABAYAJAR$8VZ&1<2,:"I55X"PMOWK8:\\
MV$3%<P\LDJB/<`"<A2G`-CAK77<;&7;KQ]I*#5IP)ZMZ'[1^%?4OAG*;+F7'
M+;?[+!LS/C;^9(W![,SD[+NT@]5K@>0SC?(\G_*CG:E4%-&-SW1_'=0<V\<[
M>@CM*U_-6+,O2TW44V[E(IEP:SXBI'+D#?N2<]-O75/.=%<QS4[_``!Y91'-
M3BGC#.C5L$/:92+7K>4:BKL20HV6*BX4K^0JE)M1V5:.8JQL5NPIP`3('3.&
MY3`(R""*A2#51?>+G*]7XY\,/)1FZ?;(IU_%W.?GGD&4:-P1:&DE(&W.Y(C$
MAP`A`>S#M$C<AS>JBI=QU#3@HKB?`KWO'1P.JG).FUSR*<_:O"<A.3O(]BUR
M948K(S%"T4+`6*9_\Y8YQWC2F2IGM>ATDJTN@Y>./8%=95QV''[`B<!U.:D>
M*R*YK^([C)R*Q_)3>(L<U'CWR;I+(]@P9F[#T.QQM8ZI>H0BC^NHR#BI(123
M^NR$FDFD]34(8X)&[R"!R%U)`/M0Y*'B^\F+3D[CEXT?*_<8YNQS3PIY+/\`
MC-RYD6R#5-P>HVB81Q3E1R]*R][V6:TFG&S#A,HD;HKJ*"F4$P(`QT!45-%M
MRM'C5\S;2#18B[)XV1>-G!!'VUFKA(JZ*Q1,`#V*)'`P;[=!UR7):ST%R)BH
M7)/EF\Q\U"M;/7^/5?5X;<4@<H)J-I5KBYXDUN#F+?$5'>*N6<K`W;/3MU!$
M6S$P[`8@@/'N5'BLP>!/C"QBC2:_REYJU*$Y+<V<Z0T;D;*-]S#$MKDUHJ]L
M8IRK3%^/ZQ/H.H&I5BF1[U-B*#=L7O60,;?L`A2R!WS3,+\>0?Q9X@L^.I[D
M7Q&IM?XV\S<%13[)&(,E8?C&5"5G)6I-C3*E$M<=7D&45,P%J:,3L^Q9$2IK
M*E.?O3]Q,XBN*$=>JQUSEY(LN<A?'CP90X]33/'W)GR/W"N8'1M3#L,KBIZR
M!VTSE=8=@<4ED'D&SAW2C)/J9J+@A0/[I2GTK4(3TZJ0SCGXD>"''6FM(!C@
M2BY.MSIJF>[95S#`1N2,B9`GU4BC*V*QSMJ0E%3/)-X)U?;2]M)'O[2```&@
M`"463^$N(O&+C;8K];,!X+QMB&Q91&%'(,G0:RQKBML^[A'I(()9./(DW5+%
MDDEP1`I"@7W3?7J5*A9\1/&+CGF:N<Z)W+F`</Y&FF/D3Y.QK&;N^.JK995.
M-2LC5PDR2D)>+=."M$G+I4Y4RF[0.H8?4=0`/PKB**;N@\=<!X+97)WA?#&,
M,4.;5$I(69QCVD5VH+3Z,,A)&B4IA2"CV)I%.,-)N!0!7N!(5U.W;O-O-`%-
M*9+4/X&SOZ%58X\^1JOQZ<-AVY<F^0'#KF_\O2]N.1J-@S)+?@SF:600`03-
M0K0X!J^<B7M(R<"&_<H`#Q'?H@P]BG7\]A64EXHN3O<5L_9.HJ@JD[BI.FKA
M(^0ZHJDH7N`Z2J9RB!BCU`0V$-2<D.2D2["?HN>WV%]O\`NSL[0[.S\.^WL[
M=NWM[>FWIMJ4Z+T>2.,IK,^!<MXJKEE?5"=OM$GZW$V*.5]ES'OI!DHF@4RN
MPB1F].'P[D0^U\.J?;KMKW;9=,LMPANI!JC8\$CP[_9F/$*W.8;1<[_Q>_V:
MT>8[JXMGL8[](C`'$8.(TG'(E:/RD5+5M5]3Y^*5A;)4Y1_6;##K)F25B9J!
M=*1DDP43,`"7V'+40#IU+L.MBK33<$743AY0:,O$5K]J^5%];3V5W):W32R=
MCRUS3@06D@@CH011<A0[=R[[B'J.VVN]QU'5T7E&2_*IBD(8YS%*0A3',<Q@
M*4I2%$QC&$>@%*4-Q^H-<?,\IX?IU8^[Q2A=\(S*S\H<C4N//!YA*9HQA#YL
M<<L,R1V2,68`NU@E:S7:Q3\>1BT,ZS,L^@DQL,5+6?XE,I"$$B;Q-9`!#8JX
MC95Y;WNZ\D?!M\VAUO&6NE:`35^EWEXX?"!4]0XD+8+8;_:N#^FL=SR:S;N)
MW>\$T%I*]S&LB@:^(W56?$TREVAM/A>QH)^4JU_Z0G'7_P!<V"MO^<67->O^
M1;Y_B5Q^HS\:HO\`J3P;_P!0V[_N)_Q*]>",L8ER?8K[@W'G'3'G$_).>\27
M?%>.,STF\VVU22-OEVS>1849^2XD%"$BL@$C#QQGK0Q'8+*II@(`?<*9?;1N
M]BP;C?W#KFU@D:\L(:#IKB_#,LKK`-0:*Y>-\PXQR>6XXQL>T6NR;QN%I+!#
M<QRR//F/`+8#K%&MN-/DN>"'-#\#B5'"U9NHT7$/(12D!+5]TZKLS`*IBDK"
M3$&N>-DHM5,0*)3LG38Q/3J``/H.K[AD8^W;Y9U,(J'=37_<M>+F":VN'P7#
M7,F8XAS2*%I!H01T(((IX+LB82]0`1Z_1]7UZY:=6%:+I*_!CE0*<Q^T2G*)
MQ$1V`A2AN81$?0"AH1]01)$[2(\_&B@"F!ZK9C\+V)[Y1..=FO=HE)%"LYCN
MBUQH%,=I@1M#0+5HG$'LR`'*"Z2MV7:_$BGT(**22@!^4$=87YS?P7NZAL0'
MF1MHXCOT;]F?VK?O[MVP;KM7$)=QOG/;:7LVJ&,Y:6C29>X\PX#N&`]0K?Q8
M?_0K:A`1Z^-VO[A]'\KKO;^UJR:8K8FOQ47F5)(WCP\KTY0Q*$5Q8\I`OKG2
M1V!""H7,ZG,"!:ZXW*3M;,29BK7MN$4RD*"TB1)-,!$%3"P!]JG(K$3`&.+%
ME7Q->8R@U9NJYL4URNY^JQC),ICKO%X2Y#8#,FR1`$ZKEXA%F23(`;G4.!0]
M=1F#51W*FM\9.4JMF/Q_\1KO4'[=]'*8)Q[79`B`E[HRSTROLZC;(1RD`B=!
MS#V.%<MS$.!3?DP';80U(RPR4C)9J3\[#U:"FK-89%I#P%=B9&=G)=^L1NQB
MX>(9K2$G(O7"@E30:,63<ZJAS"`%(41'H&I4K6[\;'&DO++Q%<PJI.L3HUSF
MKFKEGD#&Z3MI\)[<19;$=E0IUL5QU;^Y8*TFY(?8!2$O3J&H`J**,"JXQ%Y#
M;!4_!&\SQ)KG<\@L18^EN+B\,N4XRSWDK79TF$JK&G:."KK+/Y:>=1\D9(2G
M.5LJ8QPV*;:*X(#@O-YD<*)G`_\`1]+1QUKS-:4NF)L/T_(M_%JW!P^LMQB[
M7$9`R[,OC@(J.E0=NI)VJJ<RAQ0;;")M@'4TPHE%.=QURG4LW8&P]ERB2",G
M4LAXXJ-IA7**Z3CL;R<(S658N5$#G3+(1;KW&KE/?N2<(G(;8Q1#4J5W\[Y!
MK6)\)Y;R9<I)E$5:AXXN=KG9&06(@T;QT)7W[]?W#G$`,=4$>Q,@;G54,4A0
M$Q@`66*'):@N'X>;XY\8_`+R8R<Q"NX]@>2^6'-TD))!9)M383DY(616B3$T
MN=(B#"/4(Y3-[J@E("1@4`>W7$8`+C7`=ENH%,4Q0,40,4P`8I@'<#%$-P$!
M#H("&N2Y*/RE<S;/:O)'FS@RXQY#L:GBKCSCC-,;DI*P.EYR<E+O,.8QY77=
M;-'$9L64:FB4Z;@KDYU1$0$@>NHQKX(H:?''PDB.5#3FO;WO)KF1A!>"Y_<E
MJT-<X[9YE,5U&0(RM)7:<Q)P;"+?IO)]?Y@9-5P)@$4DTR[=-!BN(%5.UQIX
MG1_%"G9*@X[._)?.J=VD?O&I(<E<N2&6Y:LJ,J\G#_*:@^D(]@:#@G96P.%F
MQ0."CHQE!'<=M`**:444/A\PA1>2GBASA@7)3`LE1LK9ZY=4R>0$A%%6R$KD
M.2(VDV0*;D+)0D@"3QJ8=P(Y0(;Z-*"E$`P6$F;LV7^:\*7.3AGGE^H\Y+\!
M+!1\$7UTZ,<7=UQLROU54PKE5N*X%7>1MLHY&Z8N1`XJJMO<4-WK:BN'L3`C
M');/_P#VP?\`07Z_YO?KUR\4Z*_6BE:SGF.XS_AODJ!Y/5&,5+4LL.FM2R:A
M'LU%48G)#-D?[N659%HB8R2-RA61FKA3;;XYDF8QN]SURMP+=VRL.UW#J.;D
M?T.GZIP]A`Z+2'[RG!6[;ND?,;!@%I>G3-T#9P*U.0'G,!=W+V/)^84AE+*M
M2`'<F]`P^H!&R`[?Y-K)?[QQ$0):TTKW6K&G3F6U/B/QJ^W&G#).2V9:YCAT
MN[B:''HN[QEZRN&KQFRKN+ZF!)"S+.'BR*23=252*5DEN8![W&_T"(4C?-QF
MVBP=-$VMR\AC!W<[`"G7NKW]/^*CEO(XK&9VC:XP9;F3,1P1C5(XT.%6C2W'
M%Q`&*[?)3-I>169[#D*,9A&T&):LJ#ARMD`R;2M8KJ('8UQNV:B8Q6YY8I3O
ME@+ZG<;>@``=.Q6/T>W"!Y/F$ZWNR+WNQ<??@/`!1S_E'^:>1S7]NWR]M8&Q
M6\8RCMXAHB8!T^$:C2GQ.)S)5DOM_P"#^U_<U6Z,_25CT<N%0[Y`S=Y$OEXR
M:C7C25A9)J<R;F-EXURF\C9!LH3[::K1V@0Y1#J`EUP=%&]P?-BPC3CE0C(K
MO@N);:5LL)+7L<'`C`@@U!!Z4(JLKN3)XS)M7H7-"`9H1B.67)\?\A89JF!6
MM/Y(U-@0LG)*HH$!-DPR?!-R2;;H!5%"J"'4=6WML[=KN9-FN'$P14,3LZQ.
M)TC^@?@.?3NLI<YM6<DVZU]0=N8-=Z3'>-:/DOHVCS'$`G"X929IP!)>`,"L
M//O'#"4HA(M0[QV`1./T>OT:N9A;*YS8JN("Q68I1\S2/L*R$XH8-7Y:Y^IN
M&(5=8\"]5&Q9+EF/<)J_C2#<-C6!T98$S$;NYM59*,9";U=/"#L($-JB;]N<
M>T;*YQ_?5K3NX_*WWXGL`2K\]..%WG->6VVT,:X6I<'2NI\D32#(_'"M/A;W
M>YH]F[;"0T57(:)KT&Q;Q<+!1K&'B(UH0$FL?&1K9)FP9-DPZ$0:M42D('T%
M*&M?Y)'RR.ED-9'$DGN3B2OI_:VMO96L=G:M#+6)C6,:,FM:`&@>P`!1[LN'
M61FWE*F^<I[72C8LDN)<7@-"FD)._?XEN8WI>SJS2IQ9!7?NX>/5!,NS@7/O
M;[D[>NNNAK7HN]7#Y_\`$8O,WCK,8SA9]I2,JUBQ5K*6",DN2/#?AUF6@R1)
MBG60QX[\X$CU5"JL7WL@97X)VJ)"BH!-AQ4$55"^-[BCE[BCBG+-=SK9\:VZ
M_P"6^062\Y3;S%S:Q(5--WDD8I]+-TT;2T9R0.'$VW=.%"]@I%!<`*(AT"4`
M[K$IQX]>8?#;*-^R#XO,R8FB,191L[V]W;AMR/B+(XQ/%W.460&7EL56ZG>]
M/49M+[F.HS(B1)(J94^]9,&Y&O&E,LDIV77O?#SR?<Z6H8XYO9ZP/Q]XQ2+A
MJ7(F&^&C2\R5[R]$-'#=5Q5[#EO(:;)[5JO.H]Z;DD>W44$`V$AA%-1*<2F*
MF@Q_0:;BNCU/&V/*[&U*BT:`BZO4ZS#H?#QD)`PS1)C&QS1+<QO;;MD2AW&,
M8YS;F.8QA$1E2H//U1N6?TLI*7')N+!X,3'-V-YZ26'BP]E3R.YRS$4%6/CZ
MXH4K4::>F)9#%*2$@K>X)42K``+"9,T4]RBGN4\<K%1D[%R,)-1[*6AYA@\B
MY:*DFR+V/DXV0;J-'T>_9N"*-W;-XU5,FJD<IB*$,)3`("(:E2H.JMP/Y\<#
M)VR1?C<S-A6Z\9+%/R5EB>*/+)I=2L,42,ZZ4=2;#%V4J49]/H5@KE4RR;-X
MC]G?905UN]RI%",E&*YK-P1Y]<[9:"A_)%G##5-XRQ,S'6&<XG<1V-S2C\JO
MH1ZFZC8;*N5KN+6Q/J@9RV3<+,&2)2K;=H"DH!5B*$YY)0]5*=G?B]A#D?@:
MQ<:\I4>+E,16&O-*X2MQR*,46NMHE%).NO:FHU2`E?DZNHV24CU$2=K<R12]
MID^XAA%5*BEI7&7S+<1(]GC7CIR6XU<JL(P#=*)H+#EU!7NMY1IM?:-&Z$9"
MO;CC[Y@-D90Z:?PZ!EU#F%),HE*@GVH)L5"O!PXX<\P*OS.R[S?Y?7GCX\NN
M5<)4W$"6/\`PU[1A(!O4)U>5:/'4Y=EBNI%06ZWMF$$MS&'U`H`&@KU0*PN$
MN%7E?XIO\]0_'?+G`S[B9CY&Y8SRA^)].SA,VQB?(L\H^;QCQS7UHB-$S2,1
M;D4*4JI2K%/V'$I@U%"%`!"SYXT5SR6-KE;2<R+YP[LV-'M%<LZFSX^U'+$!
M<6E]5E&0)O9QW>I)Y$+U8(`7)3)(D!U\4*9@'L`P:D5ZJ<>J\;Q@</\`(G"'
MC5*X7R?:J7<+*^S9F7):4O0R3B<&2$R+<75AA8]0M@9L7_S5BR7*1UL04?=W
M[#&+U$,`@R6)'DU\5^5^5^0)G)_&?(.+\:V',&&'&`>2</DQC9E8#)-&B;'%
M6['D\W&J,'ZX7.C3<><K=9PGL9N=,O>`(D+H?!"*J7_[DR7X-_AQ\<R^<?AG
M]R?F7:O\O^9?=;Y%\=V=OQ/P7Q7Y3;M[^SZ-]2E,**YFBE=9VS9OT#-GS1L]
M;',0QV[M!)R@8R9RJ)F,DL4Z9C)J%`Q1$.@@`AUUSCDDB=KB<YK^X)!]X7FN
MK.TOH3;WL4<UN2#I>UKVU&(.EP(J#EA@O)^Z=6_U:@/]#1W^;:]`W"_&4\WZ
M[OQJF?Y9XW_A]C_81?L*V.;,&53,F',G8A62+6F62:?+U9Y*UY-.)?M?CFYR
MM7`.&!$%E$VSL"',F(]JA`$H]##KU6.[WEI?0WDCW2^4_4`\EP[',YTZJD\@
MX3LF\\?O=CMH8K3ZR`QE\+&Q._.;4L`):'`$M-014=5I*6*EV7&EKL^,;LQ/
M%7+'LZ^J5A:]OMI&>1"GL)/FGT'CY5F";EN8NY125+L(ZV!L;QE[9,GA+71Z
M0</%?,+?MIO=CW>XVO<&EEW#*YCAXM-/<<QX$+H:[JA4I=59PDU27=JG*1%N
MF914QAV`I$P$QC>OH!=QUVOC,L(M3@7'57P7$?-J^Q;,OB0XJ?</CU.Y+R9#
M$>S/(J9BKPE4+`U(^BX:HP[(S"CK+0C\BS%*<D8]0[Q5?VP6['"9!-L0`#"W
M-MV;<[DVUMC\-NTL+FFE7$U(]@H/:15;]?=]X,[:>(OW;>&!SMR>V1D3P'-;
M&P%K'EIJ-;]3CD"&D#J5*=^%.+O^&U!_B=7?X.U9XO+L92R#^D[\:SU_)MH_
MNMM_9,_97LPE,I]9<+NZW4ZU7W3I$C=TYA(*+BG#ENF<5$T%UF#5NHLB101,
M!3")0,.X!OKK?--(*2/<X5KB2<?M7H@L;*U<7VL,4;B*$M8UIIVP`P52ZZUZ
MDT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:_/F&XBV
M24L=-Y.XEI%GN4Q*G8X\RO6*3"/[!./$DT534R[I0\:DN[<%C2I'C7ZA2_81
M,T,(=I#CK)/!N0PV1?97S@V$"K2304)Q&/8FH\">RU*^\/Z97NZW,/*N/023
M7<I$4[(V%SM36_U<E&U-"T%CC2@(9U<5"O\`@[GC;;]'3D)U_FBN?\&:R&=\
MVNM1<V_ZP_&M7O\`3WF^7\IW#^PD_961O$GAAE3/_(*BT>_XBRC1\71KH+CD
MB=NU)G:E&NJU7EFZX5AD]EFS8CR4M,D=%F":7<<C<ZJHAVICJC;]R7;[?;I)
MK2=KKWY6AK@:D^`Z#,^SN0KY]._2/DN^<IMK/>;&YMMI:\/F?)&]@\MF+F@N
M'S/P8T=S7(%;C35JV9-F[-F@BU:-$$FK5JW3(BW;-D$RI((())@4B2**1`*4
MI0`"E``#6#7.<]Q<XU<34GQ7T9BBC@B;#"T-B8T-:!@``*``=`!@%SZA=B:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
JB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
